Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is in a strong position with its promising drug candidates GRI-0621 and GRI-0803 addressing high unmet needs in serious diseases. Despite a long development timeline and the inherent risks in the biotech industry, the potential billion-dollar market for GRI Bio's therapies presents high rewards. The company's recent fiscal Q1 2026 results were in line with expectations and it has a strong focus on developing treatments for idiopathic pulmonary fibrosis, a rapidly growing market affecting a significant number of patients. However, as a clinical stage company, GRI Bio currently generates no revenue and its financials will heavily depend on the success of its drug candidates in clinical trials and commercialization.

Bears say

GRI Bio is facing several potential risks, including balance sheet and liquidity issues, failure to gain regulatory approvals and suitable reimbursement for their product candidates. Additionally, competition in the biotech industry may hinder the company's ability to commercialize its products and changing macroeconomic factors, as well as investor sentiment, may also impact its success. The company's focus on developing GRI-0621 for IPF treatment is promising, but if the product fails to demonstrate safety and efficacy in clinical trials, it could negatively affect the company's overall outlook.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.